Broadly Neutralizing HIV Antibodies Using Consensus CDR Sequences
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV vaccine and therapeutic approaches face challenges in developing broadly neutralizing monoclonal antibodies with efficient potency and breadth against multiple HIV strains, and existing methods for cloning such antibodies are inefficient and prone to mutations that hinder their effectiveness.
Innovation Solution
Development of isolated HIV antibodies with highly conserved consensus sequences for the heavy and light chains, including specific CDR regions and insertion sequences, which enhance neutralization potency and breadth against various HIV strains, including VRC01-resistant viruses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If existing cloning methods are used to produce monoclonal antibodies, then antibody production is achieved, but the process is inefficient and prone to mutations that reduce effectiveness
Solution Approach 1:
The patent identifies and utilizes highly conserved consensus sequences in antibody heavy and light chains, representing a parameter change from variable to conserved regions. This approach transforms the cloning process by targeting invariant sequences that maintain antibody functionality while reducing mutation-prone variable regions, thereby improving both production efficiency and reliability
Solution Approach 2:
The invention uses consensus sequences as templates for antibody production, effectively copying the essential functional elements from multiple antibody variants. This copying approach allows replication of reliable antibody structures without the inefficiencies and mutations associated with traditional cloning of unique antibody sequences
2Adaptability or versatility
If monoclonal antibodies are designed to target multiple HIV strains, then neutralization breadth is improved, but potency against individual strains may be reduced
Solution Approach 1:
The patent designs monoclonal antibodies with consensus sequences that enable universal recognition across multiple HIV strains. The heavy and light chain consensus sequences are engineered to bind conserved epitopes present in diverse HIV variants, achieving multi-functionality where a single antibody design can neutralize multiple strains while maintaining effectiveness through the conserved nature of the target sequences
3Manufacturing precision
If antibody sequences are highly mutated to improve binding affinity, then potency increases, but cloning efficiency decreases and mutations may hinder effectiveness
Solution Approach 1:
Instead of starting with highly mutated sequences and attempting to clone them, the patent inverts the approach by first identifying conserved consensus sequences and then using these as the basis for antibody design. This inversion allows cloning of stable, well-defined sequences that naturally maintain high binding affinity through their conserved functional elements rather than through mutations
Data Source
AI summary
The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.